Status:
NOT_YET_RECRUITING
Genetic Variants of Annexin A2 and Cryptogenic Stroke
Lead Sponsor:
Centre Hospitalier Universitaire, Amiens
Conditions:
Annexin A2
Stroke
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Stroke is the third most common cause of death in developed countries. Various mechanisms of ischemic stroke exist. However, in young population, in a third of cases, the cause of a stroke cannot be d...
Eligibility Criteria
Inclusion
- Completed ischemic stroke defined as a rapidly developing focal neurologic deficit with no apparent cause other than a vascular origin that persisted beyond 24 hours in surviving patients
- Age from 18 years old
Exclusion
- Transient ischemic attack
- Pregnancy
Key Trial Info
Start Date :
July 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT06880107
Start Date
July 1 2025
End Date
April 1 2027
Last Update
May 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU Amiens
Amiens, France, 80054